PNC Financial Services Group
SYRE icon

PNC Financial Services Group’s Spyre Therapeutics SYRE Stock Holding History

PNC Financial Services Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.1K Buy
914
+791
+643% +$57.7K ﹤0.01% 3067
2026
Q1 		$6.2K Buy
123
+37
+43% +$1.4K ﹤0.01% 4164
2025
Q4 		$2.82K Hold
86
– – ﹤0.01% 4439
2025
Q3 		$1.44K Buy
+86
New +$1.4K ﹤0.01% 4585

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

PNC Financial Services Group's SYRE Position: Q2 2026 in Review

PNC Financial Services Group increased its Spyre Therapeutics (SYRE) stake by 643% in Q2 2026, buying an estimated $57.7K and bringing the position to 914 shares worth $81.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3067.

PNC Financial Services Group first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • PNC Financial Services Group held 914 shares of Spyre Therapeutics worth $81.1K as of Q2 2026.
  • PNC Financial Services Group bought 791 Spyre Therapeutics shares in Q2 2026, an estimated $57.7K.
  • Spyre Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3067 holding.
  • PNC Financial Services Group first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.